top of page
December 22, 2020
Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics Announce the Filing of an Application for REEQONUS™ (Favipiravir) Tablets for the Treatment of COVID-19 Under Health Canada’s Interim Order
December 2, 2020
First Patient Dosed in Appili Therapeutics’ Phase 3 Clinical Trial of Avigan® Tablets (Favipiravir) for the Treatment of COVID-19 in the United States
November 24, 2020
Health Canada Clears Appili Therapeutics for New Phase 3 Clinical Trial to Evaluate Avigan Tablets (Favipiravir) in the Prevention of COVID-19 in Exposed Individuals in the Community
November 13, 2020
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021
October 30, 2020
Appili Therapeutics Joins Dr. Reddy’s, Global Response Aid, and FUJIFILM in Advancing Avigan® Tablets for the Potential Treatment of COVID-19
October 29, 2020
Appili Therapeutics Appoints Drug Development Executive Don Cilla to the Newly Created Position of Chief Development Officer
October 27, 2020
Appili Therapeutics Announces Additional Funding for Its ATI-1701 Biodefense Program
October 20, 2020
First Participants Dosed in Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir for COVID-19 Outbreak Control in Canadian Long-Term Care Homes
September 14, 2020
Appili Therapeutics to Commence Trading on Main Board of the TSX Exchange
September 11, 2020
Appili Submits Protocol for a Phase 3 Study Evaluating Favipiravir for the Treatment of Patients with COVID-19 Infections to the US FDA
September 10, 2020
Appili Therapeutics to Participate in Upcoming Investor Conferences for H.C. Wainwright & Co. and Maxim Group LLC
August 14, 2020
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2021
August 13, 2020
Appili Therapeutics Announces Voting Results of Annual and Special Meeting of Shareholders
August 10, 2020
FDA Clears Appili Therapeutics to Expand its Phase 2 Clinical Trial of Favipiravir for the Potential Prevention of COVID-19 at U.S. Long-Term Care Facilities
July 30, 2020
Appili Prepares Canadian Long-Term Care Facilities to Enroll Participants in a Clinical Trial Evaluating Favipiravir as an Outbreak Control Agent Against COVID-19
June 10, 2020
Appili Therapeutics Announces Closing of Public Offering of $15,525,000 and Concurrent Private Placement of $1,440,000
June 5, 2020
Appili Therapeutics Announces Filing of Prospectus Supplement and Proposed Concurrent Private Placement
June 4, 2020
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering in June 2020
May 21, 2020
Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks
May 11, 2020
Appili Therapeutics Submits CTA with Health Canada to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama Chemical’s Favipiravir as a Preventative Measure Against COVID-19 in Canadian Long-Term Care Facilities
May 4, 2020
Appili Therapeutics to Present at Maxim Group’s Infectious Disease Virtual Conference
April 21, 2020
Appili Therapeutics Names Infectious Disease Specialist Yoav Golan, MD, as its Chief Medical Officer
February 27, 2020
Appili Therapeutics Reports Financial and Operational Results for Third Quarter Fiscal Year 2020 Copy
February 14, 2020
Appili Therapeutics Announces Upsizing of Previously Announced Equity Offering in February 2020
February 13, 2020
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering
February 12, 2020
Appili Therapeutics Announces Overnight Marketed Equity Offering in February 2020
January 28, 2020
Researchers Present Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2020 ASM Biothreats
January 27, 2020
Appili Therapeutics Appoints Veteran Biotech Executive Dr. Juergen Froehlich to Its Board of Directors
January 7, 2020
Appili Celebrates a Notable 2019 and Looks Ahead to Significant Milestones in 2020
bottom of page